Chan et al. created a BiKE containing an anti-CS1scFv and an anti-NKG2D scFv (CS1-NKG2D) that displayed a dose-dependent increase in specific cytotoxicity of NK cells as well as cytokine production in vitro, and significantly prolonged survival in a human multiple myeloma model [108]. Here, KLRK1 is linked to AL amyloidosis.